Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI

Launched by HENAN CANCER HOSPITAL · Feb 13, 2025

Keywords

ClinConnect Summary

This clinical trial is looking to understand how effective different types of treatments, called neoadjuvant therapies, are for patients with esophageal cancer before they undergo surgery. Neoadjuvant therapy includes various combinations of chemotherapy, radiation, and immunotherapy that help shrink the cancer before surgery. Researchers will use imaging tests like CT scans and advanced MRI to gather information about the cancer and track any changes during and after treatment. By analyzing this data, they hope to find ways to predict how well these therapies work and what the results will be after surgery.

To be eligible for this trial, participants need to be diagnosed with esophageal cancer and must have received one of the specified neoadjuvant therapies. They should also have had both CT and MRI scans before and after their treatment. However, patients with other types of cancer or those who have had previous cancer treatments will not be included. Those who join the study can expect to undergo these imaging tests and provide their medical information, which will help researchers learn more about treating esophageal cancer effectively. The trial is not yet recruiting participants, so there will be more information available soon for those interested.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Consecutive patients with histopathological diagnosis of esophageal cancer.
• • 2. Patients underwent neoadjuvant therapy before radical surgery for esophageal cancer: neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, neoadjuvant chemotherapy plus immunotherapy, neoadjuvant chemoradiotherapy plus immunotherapy.
• • 3. All patients underwent CT and multimodal MRI examinations before and after neoadjuvant therapy.
• • 4. The preoperative clinical data and postoperative pathological data are complete.
• Exclusion Criteria:
• • 1. Patients with other primary malignant tumors or previous anti-tumor treatment.
• • 2. CT and MRI images with poor quality.